Dassault Systèmes Buys ArisGlobal for $1.8 Billion

The AI compliance platform maker joins Dassault's MEDIDATA and BIOVIA life sciences units under a new leadership role.

Updated on Nov. 17, 2026 in Biotech

Dassault Systèmes Buys ArisGlobal for $1.8 Billion

Dassault Systèmes has acquired ArisGlobal, an AI-based platform provider for regulatory compliance, safety, quality and medical affairs, for $1.8 billion in cash. An additional payment of up to $200 million depends on whether AI-related sales targets are met.

Why it matters

The deal expands Dassault Systèmes' life sciences and healthcare business and links ArisGlobal's compliance tools with its existing clinical and biological software. For international pharmaceutical and biotech firms, it signals consolidation of regulatory and clinical data systems under fewer large software providers.

MEDIDATA brings clinical development experience covering 42,000 clinical trial cases and 13 million patients to the combined group. ArisGlobal's platform is described as AI-based, but its specific model parameters and technical architecture were not disclosed.

The players

Dassault Systèmes

A French software company headquartered in Vélizy-Villacoublay, known for its 3DEXPERIENCE platform and its life sciences divisions BIOVIA and MEDIDATA.

ArisGlobal

A life sciences software company that provides AI-based regulatory, safety, quality and medical affairs management tools to pharmaceutical and biotech firms.

Dr. Ashwini Zenuwine

A life sciences executive appointed senior vice president and CEO of Dassault Systèmes' life sciences division, overseeing MEDIDATA, BIOVIA and ArisGlobal.

The details

Dassault Systèmes plans to connect the technologies and data of its life sciences companies through its AI platform, 3D UNIV+RSES, integrating information from drug candidate discovery, clinical trials, manufacturing, drug safety management and patient treatment outcomes. Aman Wassan, ArisGlobal's current CEO, will continue to lead the company after the acquisition.

Timeline

  1. November 17, 2026: Dassault Systèmes announces the ArisGlobal acquisition.

  2. Upon transaction closure: The $1.8 billion cash payment becomes due.

  3. Coming years: Up to $200 million becomes payable if AI sales targets are met.

The Tech Race

The deal extends Dassault Systèmes' push into life sciences software alongside rivals building AI tools for drug development. Combining clinical, regulatory and safety data in one platform positions the company to compete for pharmaceutical software spending that has traditionally been split across separate vendors.

Pharmaceutical and biotech companies using ArisGlobal's compliance tools may see changes to how their regulatory and safety systems are supplied and priced over time. Patients and clinical trial participants are not directly affected by the acquisition itself.

The takeaway

Software that tracks a drug from discovery through patient outcomes is becoming a consolidated market, so companies choosing compliance and clinical vendors should weigh how well those systems connect. Watching how Dassault Systèmes meets its AI sales targets will show whether integrated platforms deliver on their promise.

Further reading

For more on how software is reshaping drug development, explore Biotech coverage.

Source note: This article includes information reported by 조선일보.